<p> 1</p><p>THE 21st TEL-AVIV UNIVERSITY ALZHEIMER'S DISEASE CONFERENCE Sponsored by the Adams Super Center for Brain Studies and The Rabin Center for Neurobiology Tel-Aviv University July 3-5, 2013 Program</p><p>Lectures will be held at the TAU, Faculty of Life Sciences, Britannia Building, Hall 14 WEDNESDAY, JULY 3, 2013 08:00 – 08:30 Registration Chair: Amos Korczyn, Danny Michaelson 08:30 - 08:40 Greetings: Illana Gozes, Geri Roth, Uri Ashery Session 1: APOE: The key molecule in AD Session in honor of the late Mr. Joseph and Mrs. Inez Eichenbaum</p><p>Chair: Judith Aharon, Yaniv Assaf 08:40 – 09:00 Amos Korczyn Why ApoE?</p><p>09:00 – 09:45 Allen Roses AD mitochondrial /energy hypothesis: An update of TOMMORROW, a delay of onset trial based on the TOMM40/APOE biomarkers </p><p>09:45 – 10:20 Sandro Sorbi Imaging and cognitive reserve studies predict Alzheimer dementia 10:20 – 10:55 Nick Fox Imaging the onset and progression of AD</p><p>10:55 – 11:15 Coffee break Session 2: Genetics of AD Chair: Shlomo Noy, Tali Yonash-Kimchi 11:15 – 11:35 Benedetta Nacmias The genetics of dementia</p><p>11:35 – 12:10 Ralph Martins The role of ApoE in the pathogenesis of AD 2</p><p>12:10 – 12:45 Iliya Lefterov Genome-wide mapping of RXR binding and expression profiling in brain of AD mice - </p><p>Next Generation Sequencing data and therapeutic implications </p><p>12:45 – 14:00 Lunch </p><p>Session 3: APOE Mechanisms Chair: Michael Davidson, Silvia Mandel 14:00– 14:35 Gary Landreth Nuclear receptors as therapeutic targets in AD</p><p>14:35 – 15:10 Radosveta Koldamova ApoE and Abca1: partners in β-amyloid clearance</p><p>15:10 – 15:40 Danny Michaelson Development of APOE4 targeted treatment</p><p>15:40 - 15:50 Ran Antes The retina as a window for studying apoE4 pathology </p><p>15:50– 16:10 Coffee break Session 4: Pathological Mechanisms Chair: Uri Ashery, Ory Levy</p><p>16:10 - 16:30 Inna Shvarts-Serebro Elucidating the role of environmental enrichment in mitigating AD pathology through microRNAs regulation</p><p>16:30 - 16:50 Yaara Saad β-Amyloid affects topology and viability of cultured fly neuronal networks</p><p>16:50 – 17:10 Daniel Segal A new approach for modulating neurodegenerative diseases via opening the BBB</p><p>Anat Ben-Zvi 17:30 – 17:10 Differential regulation of protein quality control networks limits proteostasis capacity during adulthood 3</p><p>THURSDAY, JULY 4, 2013</p><p>Session 5: Experimental Therapies Session in honor of the late Mrs. Miryam Lebach </p><p>Chair: Zeev Meiner, Gal Richter-Levin 08:15 – 08:35 Elhanan Pinner Potential role of CD44V10 in AD pathology</p><p>08:35 – 08:55 Illana Gozes ApoE and Activity-Dependent Neuroprotective Protein (ADNP) </p><p>08:55– 09:15 Abraham Fisher Synchronized activation of M1 muscarinic and sigma-1 receptor – A novel target in treatment of AD </p><p>09:15 – 09:35 Orly Weinreb The novel multi-target iron chelator M30 modulates HIF-1alpha and insulin signaling cascades in APP/PS1 AD mice</p><p>09:35 – 09:55 Micha Spira Rescue of AD cell pathology and synaptic transmission by anti-cancer drugs: results and prospective </p><p>09:55 – 10:15 Marta Rosin Combating chronic inflammation and oxidative stress in MCI to prevent conversion to AD</p><p>10:15 – 10:35 Polina Rabinovich Toidman Role of APP expression and processing in pathology of ALS 10:35 – 10:55 Hanna Rosenmann Safety aspects of phos-tau immunization</p><p>10:55-11:15 Coffee break </p><p>Session 6: Epidemiology and Mechanisms</p><p>Chair: Yoram Barak, Elissa Ash</p><p>11:15– 11:35 Therese Treves Is the age at onset of AD changing?</p><p>11:35 – 11:55 Ramit Ravona The association of haptoglobin genotype with cognitive function in elderly diabetic subjects</p><p>11:55 – 12:15 Tali Cukierman-Yaffe Diabetes as a disease of accelerated aging- implications for patient care and possible interventions 4</p><p>12:15 – 12:35 Michal Beeri Diabetes pharmacotherapies for AD</p><p>12:35 – 12:55 Eli Wertman Energy modulating therapy for MCI and AD - the case for hyperbaric oxygen </p><p>12:55 – 13:15 Joab Chapman Autoimmune dementia: Data from experimental antiphospholipid syndrome </p><p>13:15 – 14:00 Lunch </p><p>Session 7: Inflammation Chair : Ettie Grauer, Alon Friedman</p><p>14:00 – 14:20 Sigal Fleisher The molecular mechanisms involved in the attenuation of glial inflammation by kinins </p><p>14:20 – 14:40 Einor Ben Assayag C-reactive protein and post-stroke cognitive decline in carriers and non carriers of APOE4 genotype </p><p>14:40 – 15:00 Reuven Stein Inflammation/mitochondrial pathology</p><p>15:00 – 15:20 Dorit Farfara Gamma-secretase is important for microglia activity</p><p>15:20 – 15:40 Nechama Kosower Lipid-containing agonists for Toll-Like Receptor 2 (TLR2) inhibit Amyloid-peptide toxicity via calpastatin upregulation: a possible approach to treatment of AD</p><p>15:40 – 16:00 Coffee break </p><p>16:00 - 17:00 Session 8: Round table: Frontiers of AD therapy</p><p>Chair: Amos Korczyn, Danny Michaelson 5</p><p>FRIDAY, JULY 5, 2013: </p><p>Lectures will be held at the Psychiatric clinic* Sheba Medical Center, Tel Hashomer, Room 644 * Opposite to the Geriatric building at the rehabilitation part of the hospital</p><p>Case Presentation and Discussion </p><p>8:30-14:00 Chair: Ramit Ravona, Amos Korczyn</p><p>Supported by: Novartis, Sagol School of Neuroscience The 22nd Tel-Aviv University Alzheimer’s Disease Conference will be held on June 18-20, 2014</p><p>The 22nd Tel-Aviv University Alzheimer’s Disease Conference</p><p> will be held on, 2014</p>